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Abstract Pathogenic factors associated with maternal
hypercholesterolemia, obesity, and diabetic conditions
during pregnancy influence fetal development and predis-
pose offspring to cardiovascular disease. Animal models
have established cause–effect relationships consistent with
epidemiological findings in humans and have demonstrat-
ed, in principle, that interventions before or during
pregnancy can reduce or prevent pathogenic in utero
programming. However, little is known about the mecha-
nisms by which maternal dysmetabolic conditions enhance
disease susceptibility in offspring. Identification of these
mechanisms is rendered more difficult by the fact that
programming effects in offspring may be latent and may
require conventional risk factors and inherited genetic co-
factors to become clinically manifest. Given the increasing
prevalence of maternal risk factors, which is expected to
lead to a wave of cardiovascular disease in the coming
decades, and the length of prospective studies on develop-
mental programming in humans, greater-than-usual empha-
sis on experimental models and translational studies is
necessary.
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Introduction
The impact of gender on cardiovascular disease is well
established and it would nowadays be inconceivable to
carry out epidemiological studies on pathogenic factors or
clinical intervention trials without separate analysis of
female and male subjects. Unfortunately, identification of
gender differences at the metabolic, endocrine, and cellular
level has not yet translated into the anticipated clinical
benefits, as shown by the failure of late-onset estrogen
replacement to protect postmenopausal women against
cardiovascular disease [1–3]. Yet, in addition to differences
in pathogenetic mechanisms and responses to drugs there is
a third, far less recognized area in which a greater focus on
females promises substantial benefits.
Extensive epidemiological evidence supports the concept
that the in utero environment influences the susceptibility to
many diseases later in life. Barker and colleagues first
noticed an association between low birthweight and adult
cardiovascular disease, hypertension, and diabetes [4–6].
Later studies refined this by showing that adult cardiovas-
cular risk was associated not with low birthweight per se,
which may also reflect premature birth, but with impaired
intrauterine growth [7]. However, growth retardation is an
outcome parameter of fetal development which may result
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Naples, Italyfrom many pathogenetically diverse causes, ranging from
extreme maternal undernutrition to mechanical obstruction
of the uterine artery. In addition, fetal growth, especially in
experimental models, may also vary considerably due to
sibling competition. It is therefore increasingly recognized
that elucidation of developmental programming should
focus on maternal pathogenic factors, rather than outcome
parameters [8]. Furthermore, maternal conditions associated
with overnutrition, such as hypercholesterolemia, obesity,
hypertension, insulin resistance, and type 2 diabetes are far
more prevalent in the developed world than severe
undernutrition [9]. The increasing prevalence of maternal
obesity, gestational diabetes, and other dysmetabolic con-
ditions, their association with offspring obesity and diabetic
conditions, and the mounting evidence for atherogenic
programming by specific maternal factors in experimental
models suggest that pathogenic in utero programming may
contribute to the expected wave of cardiovascular disease in
their offspring [9–18].
On the other hand, results in experimental models
suggest that pathogenic in utero programming may be
prevented by relatively simple and safe interventions, as
well as by treatment of the underlying maternal condition.
In addition, preventive measures are likely to yield lifelong
benefits for offspring. The following will provide a brief
overview of developmental programming from a transla-
tional perspective (Fig. 1).
Programming by Maternal Undernutrition
The fact that so many different factors may lead to impaired
fetalgrowthinhumansisamajorobstacleinthesearchforthe
programming mechanisms, in particular when data from
different continents with obvious genetic and dietary differ-
ences are compared. One way to reduce confounders is to
focus on relatively homogeneous populations with a clearly
defined and temporally limited cause of growth retardation,
such asmaternal starvation for children bornduringthe Dutch
Hunger Winter (1944–1945) [19]. Although still ongoing,
studies of this population have already shown a greater
prevalence of obesity and, in some subgroups, an increased
insulin resistance. Animal models of extreme undernutrition
have established that exposure to excessive maternal
glucocorticoids (or exogenously administered dexametha-
sone) during late pregnancy plays an important role in fetal
growth retardation, as well as in adult insulin hyperglycemia,
hyperinsulinemia [20, 21], hypertension [22, 23], and
Fig. 1 Fetal programming of cardiovascular disease. Modified from reference [87]
278 J. of Cardiovasc. Trans. Res. (2009) 2:277–285atherogenesis [24]. Maternal protein restriction also induced
offspring hypertension in rats [25, 26].
However, other studies in prematurely born human
infants have indicated that increased, rather than reduced,
growth during a critical postnatal period promotes insulin
resistance [27]. This points to a major practical problem. In
contrast to conventional early predictors of adult cardio-
vascular risk, such as childhood endothelial dysfunction,
atherogenesis, obesity, and insulin resistance, the pathogen-
ic effects of fetal growth retardation cannot be corrected by
compensatory weight gain after birth. Indeed, accelerated
growth during childhood only increases later insulin
resistance and hypertension, particularly in prematurely
born children [28].
Studies of fetal undernutrition have also prompted the
hypothesis that fetal programming represents an attempt of
the fetus to adapt to adverse conditions encountered in
utero. If similar conditions, i.e. undernutrition, prevail later
in life, such adaptation would be beneficial, whereas it
would be detrimental in case of normal or abundant
nutrition [29]. If this hypothesis is correct, a therapeutical
corollary would be that low-caloric diets should prevent
cardiovascular disease in subjects born underweight for
their gestational age. This corollary is at least consistent
with the observation that postnatal overnutrition is partic-
ularly pathogenic in these subjects. The opposite corollary,
i.e., that programming by gestational hypercholesterolemia,
insulin resistance, or diabetes should be least pathogenic
under continued postnatal exposure to conventional risk
factors of these conditions seems distinctly less attractive.
Thus, although the correlation between fetal growth
retardation and adult disease is supported by the majority of
epidemiological studies and some animal studies, it is
unlikely that pathogenic programming associated with
impaired fetal growth will be preventable, unless growth
retardation itself is prevented. In contrast, other fields of
developmental programming have made significant prog-
ress towards this goal, as outlined below.
Programming by Maternal Hypercholesterolemia,
Obesity, and Diabetic Conditions
Although clinical manifestations of atherosclerosis typically
occur in adults, atherosclerotic lesions are found in most
children [30–32] and prodromal lesions, fatty streaks, may
already be formed during fetal development. The first
indication that in utero exposure to cholesterol may
program adult cardiovascular disease came from the
observation that maternal hypercholesterolemia, even if
temporary and limited to pregnancy only, is associated with
a marked increase in fatty streaks in the aorta of premature
human fetuses [16]. The same study also showed that fetal
cholesterol levels at the end of the second trimester are very
high, even in fetuses of normocholesterolemic mothers, and
decline linearly until term birth. This is consistent with the
well-documented fact that in the absence of inherited
genetic defects of lipid metabolism, such as familial
hypercholesterolemia, cholesterol levels of term-born chil-
dren are very low, even if their mothers are extensively
hypercholesterolemic. It was therefore conceivable that
fetal lesions would regress towards full term. Instead, the
Fate of Early Lesions in Children (FELIC) study, a
morphometric assessment of aortic atherosclerosis in
normocholesterolemic children who died before the age of
14, demonstrated that maternal hypercholesterolemia is
associated with greater atherogenesis throughout childhood
[17]. This observation could not be explained by conven-
tional risk factors in mothers or children and suggested
programming by maternal hypercholesterolemia or the
ensuing increase in oxidative stress. A retrospective study
correlating maternal cholesterol levels with the severity of
myocardial infarction in young adults is currently under
way to establish the effect of fetal programming on clinical
manifestations of atherosclerosis.
In the human subjects of the FELIC study, genetic traits
inherited from hypercholesterolemic mothers are likely to
have contributed to increased atherosclerosis in their
offspring. Direct experimental evidence for the causal role
of maternal hypercholesterolemia was obtained in geneti-
cally more uniform models. For example, temporary, diet-
induced maternal hypercholesterolemia prior to and during
pregnancy led to dose-dependent increases in fetal lesion
formation [33] and postnatal atherogenesis in NZW rabbits
[34]. Conversely, maternal cholesterol-lowering with cho-
lestyramine, considered safe during pregnancy, or with a
natural antioxidant, vitamin E, greatly reduced offspring
atherosclerosis [33, 34]. Similarly, maternal treatment with
a statin during pregnancy (contraindicated in humans)
reduced atherogenic programming in mice [35]. The
protective effect of antioxidants and cholesterol-lowering
drugs also indicated an important role of oxidative stress in
developmental programming, which is discussed in the
following chapter.
Mouse and rat models also provided valuable insights into
fetal programming. For example, moderate maternal hyper-
cholesterolemialedtopersistentchangesingeneexpressionin
the arterial intima and media prior to histologically detectable
atherogenesis [36]. It also enhanced offspring atherosclerosis
in apoE-deficient (ApoE
−/−)m i c e[ 37], although others had
failed to see an effect in this strain [38]. One of the most
important results was obtained by a comparison of hetero-
zygous offspring generated by crossing wild-type apoE
+/+
females with apoE
−/− males, and vice versa. Thus, all
offspring were genetically identical, but exposed to either
normal or mildly hypercholesterolemic conditions in utero,
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lesterolemia achievable in apoE
+/− offspring was insufficient
to induce significant atherosclerosis, but pathogenic
programming manifested itself in the form of dramatically
increased carotid atherosclerosis, once an additional athero-
genic stimulus was added, in this case a non-constricting
carotid cuff [39]. These results highlight the fact that fetal
programming effects may be latent and become apparent
only in the presence of additional or more severe conven-
tional risk factors, or, as shown recently in a model of
spontaneous stroke, a combination of inherited genetic
susceptibility and dietary factors acting synergistically
[40, 41].
Wild-type rat models do not usually develop sufficiently
high plasma cholesterol levels to cause atherosclerosis, but
have indicated other mechanisms by which maternal high-
fat, high-cholesterol diets during pregnancy may promote
cardiovascular disease, such as impaired vascular reactivity
in offspring [42–45]. Some of these effects were enhanced
by maternal diabetes [42], and conversely, high-fat diets
promoted insulin resistance in offspring [46]. Maternal
exposure of rats to a high carbohydrate diet resulted in
similar programming of hyperinsulinemia, which could be
reduced by low-carbohydrate diets [47].
Murine models of obesity and gestational diabetes have
identified programming of factors involved in insulin
signaling and insulin resistance itself [48]. However,
caution is indicated when extrapolating the effects of
high-fat diets and obesity in mice to humans, because the
C57\BL6 strains appears to be genetically predisposed to
type 2 diabetes [49, 50]. Furthermore, in many rodent
models a clear distinction between pathogenic factors is
impossible, because standard high-fat, high-cholesterol
diets induce not just hypercholesterolemia but also obesity
and insulin resistance [51]. Such a distinction is less
important for translational purposes, though, because
obesity, insulin resistance and combined hyperlipidemia
are prevalent in many human mothers, and synergism of
pathogenic mechanism programmed in utero is likely.
Putative Mechanisms of Early-life Programming
Hypercholesterolemia is associated with enhanced lipid
peroxidation and a wide range of oxidized fatty acids and
other markers of lipid peroxidation are increased in fetal
plasma and aortic lesions [16, 52–54]. The first indication
that increased oxidative stress might play a role in
atherogenic programming was provided by a study in
premature human fetuses which showed that intracranial
arteries, which had higher activities of antioxidant enzymes,
developed less atherosclerosis in response to maternal
hypercholesterolemia than extracranial arteries [52]. A
similar observation later linked an acceleration of intracra-
nial atherogenesis in elderly human subject to an age-
related decrease in antioxidative protection [55]. Given that
OxLDL enhances adult atherogenesis by a number of
mechanisms, including interference with many oxidation-
sensitive nuclear signaling pathways [56], we proposed that
oxidative stress is important in developmental program-
ming by maternal hypercholesterolemia [17, 57]. This
notion was supported by the prevention of atherogenic
programming achieved by maternal treatments which
reduced lipid peroxidation either directly (antioxidants) or
by reducing plasma cholesterol (cholestyramine, statins)
[33, 34]. Later studies also established an involvement of
oxidative stress in the fetal programming of vascular
dysfunction and hypertension [58].
Lipid peroxidation products (reactive aldehydes,
ketones, and oxidized phospholipids) modify biological
properties of many proteins by forming adducts with free
amino groups. They may also affect DNA. In fact, much
attention has focused on DNA methylation and other
epigenetic effects [59]. In utero conditions indeed result in
specific epigenetic changes [60, 61]. However, there is no
evidence that epigenetic changes actually cause or contrib-
ute to increased disease manifestation in offspring. Another
possibly related mechanism is the alteration of mitochon-
drial DNA [46]. This is intuitively attractive, because
mitochondrial DNA is inherited exclusively from the
mother and would therefore allow the transfer of fetal
programming “memory” to successive generations.
Finally, we have recently shown in both rabbit and
murine models that immune mechanisms may influence
fetal programming. Maternal immunization with homolo-
gous OxLDL prior to hypercholesterolemic pregnancy
effectively reduced atherogenic programming in their
offspring, probably by reducing fetal exposure to circulat-
ing mildly oxidized LDL [18]. In fact, increased formation
of antibodies to oxidation-specific epitopes had previously
been shown to reduce atherogenesis in adult animals, in
part by formation and rapid elimination of immune
complexes [62]. Unexpectedly, the beneficial effect was
not limited to offspring of hypercholesterolemic mothers.
Furthermore, titers of protective IgM antibodies and IgM-
LDL immune complexes were persistently increased in
adult offspring of immunized mothers. Naïve adult off-
spring never exposed to increased oxidative stress also
showed markedly increased B cell-dependent IgM and IgG
responses to antigenic challenge with selective oxidation-
specific epitopes. These results demonstrate that immature
fetal lymphocytes are programmed in utero. Previously, it
was presumed that maternal adaptive immunity protects the
neonate mainly by transplacental passage of maternal IgG,
and in utero programming of B and T cells had only be
shown in connection with increased IgE responses to
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in utero programming of beneficial IgM and IgG responses
by maternal immunization prior to pregnancy.
Elucidation of fetal immune programming is still in its
infancy, but the above data also emphasize the importance
of inflammation in in utero programming. Whether its role
will be as complex as in atherosclerosis remains to be seen
[63]. All of the maternal conditions of overnutrition
discussed above promote inflammation. Furthermore,
markers of inflammation, such as CRP, correlate with the
extent of fetal atherogenesis in humans [64]. Similarly,
increased CRP was observed in infants of mothers with
type 1 diabetes [65]. Thus, proinflammatory cytokines will
have to be considered as potential causes of programming,
and makers of inflammation as potential predictors.
A good example that fetal programming by the same
maternal factor may involve not just one but many of the
mechanisms described above is provided by maternal
smoking. This has been shown to increase formation of
reactive oxygen species or reduce antioxidant activities [66,
67], to affect immune mechanisms [68], to impair the
development of the lung and heart [69, 70], to affect
mitochondrial DNA [67], and to enhance hypertension [71]
in human and animal offspring.
The Role of the Placenta
The atherogenic programming effect of maternal hypercho-
lesterolemia and the observation of strikingly high fetal
cholesterol levels at the end of second trimester [16] raised
new interest in maternal–fetal cholesterol transport. Could it
be that maternal cholesterol crosses the placental barrier,
which is impenetrable for lipoprotein particles? This
possibility had already been postulated because of the
survival of human fetuses with the Smith Lemli Opitz
syndrome, which cannot synthesize cholesterol and there-
fore depend on maternal cholesterol [72]. Evidence for
maternal–fetal cholesterol transport had also been provided
by the identification of active transport mechanisms on the
maternal side of the placenta in rabbits [73] and hamsters
[74]. The last step in transplacental cholesterol transport
mechanism—the export from endothelial cells lining the
placental villi into the lumen of fetal microvessels—has
recently been elucidated [75]. Results indicate that regula-
tion of these mechanisms by increased fetal demand for
cholesterol differs from that induced by maternal hyper-
cholesterolemia [76]. Increased cholesterol transport, at
least during parts of gestation, may therefore constitute one
mechanism by which maternal hypercholesterolemia affects
fetal programming.
In addition to maternal factors crossing the placental
barrier, it is important to remember that the placenta is not a
passive filter between mother and fetus, but that it can be
both target and source of pathogenic factors affecting the
fetus. A recent comparison of the activities of antioxidant
enzymes in human maternal and fetal plasma and placental
tissue from normo- and hypercholesterolemic subjects has
shown that the placenta can both protect against, and
contribute to, fetal oxidative stress [77]. Unfortunately, the
placenta of many lower animal models shows significant
anatomical and functional differences, compared to the
human placenta, which complicates the investigation of its
role in developmental programming.
Programming of Hypertension
Hypertension is a major risk factor of cardiovascular
disease that is influenced by early-life programming, and
hypertension during pregnancy is a leading cause of
maternal and perinatal mortality. However, there is little
evidence that maternal hypertension directly affects fetal
programming. In fact, most insights into in utero modula-
tion of hypertensive mechanisms were obtained in models
of maternal hypercholesterolemia or obesity [42, 44, 78,
79] or impaired fetal growth [22, 80, 81]. Nevertheless,
fetal exposure to high salt concentrations promotes off-
spring hypertension in both salt-sensitive and salt-resistant
rat strains [82, 83]. A more complex causality was recently
established in a novel rat model combining genetic salt
susceptibility, expression of human cholesterol ester trans-
fer protein, and mild dietary salt exposure [40]. Salt
exposure began during pregnancy, at weaning, or early
adult age. Both fetal and at weaning onset of salt exposure
resulted in extensive spontaneous stroke. Thus, the critical
period was not limited to fetal development, but included
lactation and infancy [40, 41].
A Word of Caution
Throughout this review, the authors have taken some liberty
with the terms referring to developmental programming.
This reflects the present lack of understanding not only of
the mechanisms involved, but also of the timeframe. Fetal
(i.e., in utero) programming and programming during
lactation probably constitute a single entity. Childhood
conditions also markedly influence adult disease manifes-
tation and may enhance or attenuate the effects of fetal
programming. Again, the mechanisms are largely unknown,
but conditioning during childhood clearly represents a
different entity than fetal programming. Finally, we should
be aware that early-life exposure to pathogenic factors
may predispose one to adult disease manifestation by at
least three very different mechanisms. First, by actual
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gene expression or epigenetic changes. Second, by im-
paired development of tissues or organs, which may persist
over time in the form of altered cellular composition or
reduced functionality. The latter is probably true for the
lungs of asthmatic children whose mothers smoked during
pregnancy. Third, neonates/infants may just be particularly
vulnerable to specific injury, e.g. by toxins or free radicals.
In this case, the same insult would cause lesser damage in
adults, but the mechanisms would not be different, and no
programming would be involved. From a translational
perspective, this distinction should not be very relevant,
as long as we can find ways to prevent the pathogenic
events in the fetus from occurring.
Conclusion
Increasing evidence indicates that maternal hypercholesterol-
emia, obesity, and diabetic conditions during pregnancy
influence fetal development and predispose offspring to
cardiovascular disease. Animal models have established
cause–effect relationships for some maternal factors and led
to the identification of specific epigenetic changes, but the
nature of fetal programming and the mechanisms by which
they actually promote adult disease remain largely unknown.
Similarly, most of the maternal factors responsible for fetal
programming remain unknown. The National Children's
Study, a prospective study designed to document maternal
pathologies and exposure to environmental risk factors and to
follow 100,000 of their children to the age of 25 years, will
probably identify many more of these factors and establish
better correlations with offspring effects [84–86]. Sadly, this
will come rather late for the children of the increasing
number of current high-risk mothers. A greater-than-usual
emphasis on experimental models and on translational
studies is indicated in order to explore the mechanisms and
to identify potential targets for intervention [87].
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